Seminars in Diagnostic Pathology
Volume 25, Issue 4 , Pages 262-273, November 2008

Targeted therapies in gynecologic cancers and melanoma

Departments of Medical Oncology, Dermatology, and Pathology, and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida–IRB Lleida, Lleida, Spain

The article reviews the main molecular pathology alterations of endometrial and ovarian carcinomas and melanoma. Several promising drugs targeting the genes most frequently altered in these tumors are under consideration. The most promising signaling pathways to be targeted for therapies in these tumors are the tyrosine kinase receptor (EGFR, HER2, c-KIT), the RAS/B-RAF/MAPK, the PI3K–mTOR, and apoptosis signaling pathways.

Keywords: Endometrial carcinoma, Ovarian carcinoma, Melanoma, Target therapies

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0740-2570(08)00062-2

doi:10.1053/j.semdp.2008.07.008

Seminars in Diagnostic Pathology
Volume 25, Issue 4 , Pages 262-273, November 2008

Article Tools

* Image Usage & Resolution